Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Experimental and clinical evidence supports the role of inflammation in atherosclerosis and its complications. Colchicine is an orally administered, potent antiinflammatory medication that is indicated for the treatment of gout and pericarditis. METHODS: We performed a randomized, double-blind trial involving patients recruited within 30 days after a myocardial infarction. The patients were randomly assigned to receive either low-dose colchicine (0.5 mg once daily) or placebo. The primary efficacy end point was a composite of death from cardiovascular causes, resuscitated cardiac arrest, myocardial infarction, stroke, or urgent hospitalization for angina leading to coronary revascularization. The components of the primary end point and safety were also assessed. RESULTS: A total of 4745 patients were enrolled; 2366 patients were assigned to the colchicine group, and 2379 to the placebo group. Patients were followed for a median of 22.6 months. The primary end point occurred in 5.5% of the patients in the colchicine group, as compared with 7.1% of those in the placebo group (hazard ratio, 0.77; 95% confidence interval [CI], 0.61 to 0.96; P = 0.02). The hazard ratios were 0.84 (95% CI, 0.46 to 1.52) for death from cardiovascular causes, 0.83 (95% CI, 0.25 to 2.73) for resuscitated cardiac arrest, 0.91 (95% CI, 0.68 to 1.21) for myocardial infarction, 0.26 (95% CI, 0.10 to 0.70) for stroke, and 0.50 (95% CI, 0.31 to 0.81) for urgent hospitalization for angina leading to coronary revascularization. Diarrhea was reported in 9.7% of the patients in the colchicine group and in 8.9% of those in the placebo group (P = 0.35). Pneumonia was reported as a serious adverse event in 0.9% of the patients in the colchicine group and in 0.4% of those in the placebo group (P = 0.03). CONCLUSIONS: Among patients with a recent myocardial infarction, colchicine at a dose of 0.5 mg daily led to a significantly lower risk of ischemic cardiovascular events than placebo. (Funded by the Government of Quebec and others; COLCOT ClinicalTrials.gov number, NCT02551094.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Trials have shown that targeted inhibition of this inflammatory pathway, as measured by changes in CRP concentrations, can reduce the rate of cardiovascular events.5, 6, 7”
From Effects of once-weekly semaglutide 2.4 mg on C-reactive protein in adults with overweight or obesity (STEP 1, 2, and 3): exploratory analyses of three randomised, double-blind, placebo-controlled, phase 3 trials (2023) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This was also not an isolated finding as a similar reduction of CVD risk linked to reduction of inflammation was reported in the COLCOT trial when participants were given low‐dose colchicine (a standard anti‐inflammatory drug) (Tardif et al., 2019).”
From Treatment of periodontitis and C ‐reactive protein: A systematic review and meta‐analysis of randomized clinical trials (2023) · cites this paper as Tardif et al., 2019
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Reduction in LDL-C has been strongly associated with improved cardiovascular outcomes, and 3 recent trials have demonstrated favorable effects with anti-inflammatory therapies.[21][22][23][24]”
From Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients (2023) · cites this paper as [23]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Reduction in LDL-C has been strongly associated with improved cardiovascular outcomes, and 3 recent trials have demonstrated favorable effects with anti-inflammatory therapies.[21][22][23][24]”
From Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients (2023) · cites this paper as [23]
Experimental — accuracy not yet measuredIn the citing paper
“However, when appraised together, the evidence supports apolipoprotein B as being necessary for lipid-mediated atherogenesis by LDL-C to occur. 57,58 .”
From Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development (2021) · cites this paper as [58]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707914 · Cited by 9,482
Inflammation, Atherosclerosis, and Coronary Artery Disease
Hansson, G. K. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043430 · Cited by 8,773
Cox’s regression model for counting processes: A large sample study
Andersen, P. K., & Gill, R. D. (1982) · The Annals of Statistics · doi:10.1214/aos/1176345976 · Cited by 4,419
The Robust Inference for the Cox Proportional Hazards Model
Lin, D. Y., & Wei, L. J. (1989) · Journal of the American Statistical Association · doi:10.1080/01621459.1989.10478874 · Cited by 2,695
Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain
Ravelli, R. B. G., Gigant, B., Curmi, P. A., Jourdain, I., Lachkar, S., Sobel, A., & Knossow, M. (2004) · Nature · doi:10.1038/nature02393 · Cited by 1,630
Low-Dose Methotrexate for the Prevention of Atherosclerotic Events
Ridker, P. M., Everett, B. M., Pradhan, A., MacFadyen, J. G., Solomon, D. H., Zaharris, E., Mam, V., Hasan, A., Rosenberg, Y., Iturriaga, E., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1809798 · Cited by 1,317
Self-citationLow-Dose Colchicine for Secondary Prevention of Cardiovascular Disease
Nidorf, S. M., Eikelboom, J. W., Budgeon, C. A., & Thompson, P. L. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.10.027 · Cited by 1,054
Semiparametric regression for the mean and rate functions of recurrent events
Lin, D. Y., Wei, L. J., Yang, I., & Ying, Z. (2000) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/1467-9868.00259 · Cited by 969
Imazio, M., Bobbio, M., Cecchi, E., Demarie, D., Demichelis, B., Pomari, F., Moratti, M., Gaschino, G., Giammaria, M., Ghisio, A., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.542738 · Cited by 614
Cited by
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Benetos, A., Biffi, A., Boavida, J.-M., Capodanno, D., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab484 · Cited by 6,485
2023 ESC Guidelines for the management of acute coronary syndromes
Byrne, R. A., Rossello, X., Coughlan, J. J., Barbato, E., Berry, C., Chieffo, A., Claeys, M. J., Dan, G.-A., Dweck, M. R., Galbraith, M., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad191 · Cited by 5,333
Self-citationThe changing landscape of atherosclerosis
Libby, P. (2021) · Nature · doi:10.1038/s41586-021-03392-8 · Cited by 2,873
2024 ESC Guidelines for the management of chronic coronary syndromes
Vrints, C., Andreotti, F., Koskinas, K. C., Rossello, X., Adamo, M., Ainslie, J., Banning, A. P., Budaj, A., Buechel, R. R., Chiariello, G. A., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae177 · Cited by 2,774
Colchicine in Patients with Chronic Coronary Disease
Nidorf, S. M., Fiolet, A. T. L., Mosterd, A., Eikelboom, J. W., Schut, A., Opstal, T. S. J., The, S. H. K., Xu, X.-F., Ireland, M. A., Lenderink, T., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2021372 · Cited by 2,299
Virani, S. S., Newby, L. K., Arnold, S. V., Bittner, V., Brewer, L. C., Demeter, S. H., Dixon, D. L., Fearon, W. F., Hess, B., Johnson, H. M., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001168 · Cited by 1,598
Chait, A., & den Hartigh, L. J. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.00022 · Cited by 1,529
“A more recent study showed that colchicine, an old drug that has powerful anti-inflammatory properties, reduced recurrent ischemic events when administered after a myocardial infarction (660).”
BackgroundImpact of sex and gender on COVID-19 outcomes in Europe
Gebhard, C., Regitz-Zagrosek, V., Neuhauser, H. K., Morgan, R., & Klein, S. L. (2020) · Biology of Sex Differences · doi:10.1186/s13293-020-00304-9 · Cited by 1,306
“The drug has recently regained popularity when it was shown that colchicine reduced the risk of ischemic cardiovascular events in patients with a recent myocardial infarction [143].”
BackgroundInflammation and atherosclerosis: signaling pathways and therapeutic intervention
Kong, P., Cui, Z.-Y., Huang, X.-F., Zhang, D.-D., Guo, R.-J., & Han, M. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00955-7 · Cited by 1,183
“and human biomarker and experimental work to clinical fruition.(355,366,378) Indeed, the recent evidence that interventions of anti-inflammation can forestall the complications of atherosclerosis scratches merely the surface of the potential as novel therapeutics.”
BackgroundXu, S., Ilyas, I., Little, P. J., Li, H., Kamato, D., Zheng, X., Luo, S., Li, Z., Liu, P., Han, J., et al. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000096 · Cited by 1,142
Metabolic Inflammation and Insulin Resistance in Obesity
Wu, H., & Ballantyne, C. M. (2020) · Circulation Research · doi:10.1161/circresaha.119.315896 · Cited by 1,059
Interplay between inflammation and thrombosis in cardiovascular pathology
Stark, K., & Massberg, S. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00552-1 · Cited by 1,033
Targeting inflammation in atherosclerosis — from experimental insights to the clinic
Soehnlein, O., & Libby, P. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00198-1 · Cited by 1,019
2024 ESC Guidelines for the management of peripheral arterial and aortic diseases
Mazzolai, L., Teixido-Tura, G., Lanzi, S., Boc, V., Bossone, E., Brodmann, M., Bura-Rivière, A., De Backer, J., Deglise, S., Della Corte, A., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae179 · Cited by 993
Signaling pathways and targeted therapy for myocardial infarction
Zhang, Q., Wang, L., Wang, S., Cheng, H., Xu, L., Pei, G., Wang, Y., Fu, C., Jiang, Y., He, C., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00925-z · Cited by 831
Reappraising the role of inflammation in heart failure
Adamo, L., Rocha-Resende, C., Prabhu, S. D., & Mann, D. L. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-019-0315-x · Cited by 765
Ridker, P. M., Devalaraja, M., Baeres, F. M. M., Engelmann, M. D. M., Hovingh, G. K., Ivkovic, M., Lo, L., Kling, D., Pergola, P., Raj, D., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00520-1 · Cited by 737
Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease
Abbate, A., Toldo, S., Marchetti, C., Kron, J., Van Tassell, B. W., & Dinarello, C. A. (2020) · Circulation Research · doi:10.1161/circresaha.120.315937 · Cited by 730
The Role of Inflammation in Cardiovascular Disease
Henein, M. Y., Vancheri, S., Longo, G., & Vancheri, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232112906 · Cited by 724
Interleukin-6 Signaling and Anti-Interleukin-6 Therapeutics in Cardiovascular Disease
Ridker, P. M., & Rane, M. (2021) · Circulation Research · doi:10.1161/circresaha.121.319077 · Cited by 691
Ridker, P. M., Bhatt, D. L., Pradhan, A. D., Glynn, R. J., MacFadyen, J. G., & Nissen, S. E. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00215-5 · Cited by 672
Rao, S. V., O’Donoghue, M. L., Ruel, M., Rab, T., Tamis-Holland, J. E., Alexander, J. H., Baber, U., Baker, H., Cohen, M. G., Cruz-Ruiz, M., et al. (2025) · Circulation · doi:10.1161/cir.0000000000001309 · Cited by 625
2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes
Rao, S. V., O’Donoghue, M. L., Ruel, M., Rab, T., Tamis-Holland, J. E., Alexander, J. H., Baber, U., Baker, H., Cohen, M. G., Cruz-Ruiz, M., et al. (2025) · JACC · doi:10.1016/j.jacc.2024.11.009 · Cited by 552
Virani, S. S., Newby, L. K., Arnold, S. V., Bittner, V., Brewer, L. C., Demeter, S. H., Dixon, D. L., Fearon, W. F., Hess, B., Johnson, H. M., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.04.003 · Cited by 596
How the immune system shapes atherosclerosis: roles of innate and adaptive immunity
Roy, P., Orecchioni, M., & Ley, K. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00584-1 · Cited by 565
Myocardial ischemia-reperfusion injury and the influence of inflammation
Algoet, M., Janssens, S., Himmelreich, U., Gsell, W., Pusovnik, M., Van den Eynde, J., & Oosterlinck, W. (2023) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2022.02.005 · Cited by 545
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Benetos, A., Biffi, A., Boavida, J.-M., Capodanno, D., et al. (2022) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwab154 · Cited by 542
Macrophage-targeted nanomedicine for the diagnosis and treatment of atherosclerosis
Chen, W., Schilperoort, M., Cao, Y., Shi, J., Tabas, I., & Tao, W. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00629-x · Cited by 518
COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs
TUFAN, A., AVANOĞLU GÜLER, A., & MATUCCI-CERINIC, M. (2020) · TURKISH JOURNAL OF MEDICAL SCIENCES · doi:10.3906/sag-2004-168 · Cited by 495
“In recent years, colchicine has attracted attention in the management of cardiovascular diseases by suppressing their inflammatory component [92].”
BackgroundBergmark, B. A., Mathenge, N., Merlini, P. A., Lawrence-Wright, M. B., & Giugliano, R. P. (2022) · The Lancet · doi:10.1016/s0140-6736(21)02391-6 · Cited by 445
Inflammation and cardiovascular disease: From mechanisms to therapeutics
Alfaddagh, A., Martin, S. S., Leucker, T. M., Michos, E. D., Blaha, M. J., Lowenstein, C. J., Jones, S. R., & Toth, P. P. (2020) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2020.100130 · Cited by 473
“cantly reduced ASCVD-related events in patients with high ASCVD risk [17].”
BackgroundInflammation in atherosclerosis: pathophysiology and mechanisms
Ajoolabady, A., Pratico, D., Lin, L., Mantzoros, C. S., Bahijri, S., Tuomilehto, J., & Ren, J. (2024) · Cell Death & Disease · doi:10.1038/s41419-024-07166-8 · Cited by 447
Nicholls, S. J., Kataoka, Y., Nissen, S. E., Prati, F., Windecker, S., Puri, R., Hucko, T., Aradi, D., Herrman, J.-P. R., Hermanides, R. S., et al. (2022) · JACC: Cardiovascular Imaging · doi:10.1016/j.jcmg.2022.03.002 · Cited by 458
Conrad, N., Verbeke, G., Molenberghs, G., Goetschalckx, L., Callender, T., Cambridge, G., Mason, J. C., Rahimi, K., McMurray, J. J. V., & Verbakel, J. Y. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01349-6 · Cited by 445
Broch, K., Anstensrud, A. K., Woxholt, S., Sharma, K., Tøllefsen, I. M., Bendz, B., Aakhus, S., Ueland, T., Amundsen, B. H., Damås, J. K., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.02.049 · Cited by 446
Targeting cardiovascular inflammation: next steps in clinical translation
Lawler, P. R., Bhatt, D. L., Godoy, L. C., Lüscher, T. F., Bonow, R. O., Verma, S., & Ridker, P. M. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa099 · Cited by 443
Molecular Basis of Atrial Fibrillation Pathophysiology and Therapy: A Translational Perspective
Nattel, S., Heijman, J., Zhou, L., & Dobrev, D. (2020) · Circulation Research · doi:10.1161/circresaha.120.316363 · Cited by 440
Therapeutic strategies targeting inflammation and immunity in atherosclerosis: how to proceed?
Engelen, S. E., Robinson, A. J. B., Zurke, Y.-X., & Monaco, C. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00668-4 · Cited by 425
Inflammation during the life cycle of the atherosclerotic plaque
Libby, P. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab303 · Cited by 414
The role of the NLRP3 inflammasome and pyroptosis in cardiovascular diseases
Toldo, S., & Abbate, A. (2024) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00946-3 · Cited by 411
Döring, Y., Libby, P., & Soehnlein, O. (2020) · Circulation Research · doi:10.1161/circresaha.120.315931 · Cited by 410
Drosos, G. C., Vedder, D., Houben, E., Boekel, L., Atzeni, F., Badreh, S., Boumpas, D. T., Brodin, N., Bruce, I. N., González-Gay, M. Á., et al. (2022) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2021-221733 · Cited by 406
Emerging Mechanisms of Cardiovascular Protection for the Omega-3 Fatty Acid Eicosapentaenoic Acid
Mason, R. P., Libby, P., & Bhatt, D. L. (2020) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.119.313286 · Cited by 407
Sex as a Biological Variable in Atherosclerosis
Man, J. J., Beckman, J. A., & Jaffe, I. Z. (2020) · Circulation Research · doi:10.1161/circresaha.120.315930 · Cited by 402
Colchicine in Patients With Acute Coronary Syndrome: The Australian COPS Randomized Clinical Trial
Tong, D. C., Quinn, S., Nasis, A., Hiew, C., Roberts-Thomson, P., Adams, H., Sriamareswaran, R., Htun, N. M., Wilson, W., Stub, D., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.050771 · Cited by 393
Neutrophil extracellular traps: from physiology to pathology
Hidalgo, A., Libby, P., Soehnlein, O., Aramburu, I. V., Papayannopoulos, V., & Silvestre-Roig, C. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvab329 · Cited by 401
Mechanisms of cognitive dysfunction in CKD
Viggiano, D., Wagner, C. A., Martino, G., Nedergaard, M., Zoccali, C., Unwin, R., & Capasso, G. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-020-0266-9 · Cited by 392
Deftereos, S. G., Giannopoulos, G., Vrachatis, D. A., Siasos, G. D., Giotaki, S. G., Gargalianos, P., Metallidis, S., Sianos, G., Baltagiannis, S., Panagopoulos, P., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.13136 · Cited by 387
“Median (IQR) hospitalization duration was 12 (9-22) days in the colchicine groups and 13 (9-18) days in the control group (P = .”
BackgroundAtherosclerotic Plaque Healing
Vergallo, R., & Crea, F. (2020) · New England Journal of Medicine · doi:10.1056/nejmra2000317 · Cited by 379
Bushnell, C., Kernan, W. N., Sharrief, A. Z., Chaturvedi, S., Cole, J. W., Cornwell, W. K., Cosby-Gaither, C., Doyle, S., Goldstein, L. B., Lennon, O., et al. (2024) · Stroke · doi:10.1161/str.0000000000000475 · Cited by 360
Inflammation in acute myocardial infarction: the good, the bad and the ugly
Matter, M. A., Paneni, F., Libby, P., Frantz, S., Stähli, B. E., Templin, C., Mengozzi, A., Wang, Y.-J., Kündig, T. M., Räber, L., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehad486 · Cited by 357
“70 Complementary to COLCOT, the smaller Low Dose Colchicine for Secondary Prevention of Cardiovascular Disease (LoDoCo2) trial showed that low-dose colchicine improved outcome in patients with chronic coronary syndromes (CCS).”
BackgroundMacrophages in cardiovascular diseases: molecular mechanisms and therapeutic targets
Chen, R., Zhang, H., Tang, B., Luo, Y., Yang, Y., Zhong, X., Chen, S., Xu, X., Huang, S., & Liu, C. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01840-1 · Cited by 349
Adamstein, N. H., MacFadyen, J. G., Rose, L. M., Glynn, R. J., Dey, A. K., Libby, P., Tabas, I. A., Mehta, N. N., & Ridker, P. M. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa1034 · Cited by 356
Colchicine in Acute Myocardial Infarction
Jolly, S. S., d’Entremont, M.-A., Lee, S. F., Mian, R., Tyrwhitt, J., Kedev, S., Montalescot, G., Cornel, J. H., Stanković, G., Moreno, R., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2405922 · Cited by 332
Mackenzie, I. S., Ford, I., Nuki, G., Hallas, J., Hawkey, C. J., Webster, J., Ralston, S. H., Walters, M., Robertson, M., De Caterina, R., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32234-0 · Cited by 352
Tardif, J.-C., Bouabdallaoui, N., L'Allier, P. L., Gaudet, D., Shah, B., Pillinger, M. H., Lopez-Sendon, J., da Luz, P., Verret, L., Audet, S., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00222-8 · Cited by 353
Self-citationInflamm-ageing: the role of inflammation in age-dependent cardiovascular disease
Liberale, L., Montecucco, F., Tardif, J.-C., Libby, P., & Camici, G. G. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz961 · Cited by 345
“also increased in the colchicine-treated group, but infectious deaths and septic shock did not differ in the two groups.(139) Currently, the”
BackgroundResultInfluentialSelf-citationSummary of Updated Recommendations for Primary Prevention of Cardiovascular Disease in Women
Cho, L., Davis, M., Elgendy, I., Epps, K., Lindley, K. J., Mehta, P. K., Michos, E. D., Minissian, M., Pepine, C., Vaccarino, V., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.03.060 · Cited by 347
Immune Pathways in Etiology, Acute Phase, and Chronic Sequelae of Ischemic Stroke
Endres, M., Moro, M. A., Nolte, C. H., Dames, C., Buckwalter, M. S., & Meisel, A. (2022) · Circulation Research · doi:10.1161/circresaha.121.319994 · Cited by 340
Bienvenu, L. A., Noonan, J., Wang, X., & Peter, K. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvaa284 · Cited by 338
Targeting the NLRP3 inflammasome in cardiovascular diseases
Toldo, S., Mezzaroma, E., Buckley, L. F., Potere, N., Di Nisio, M., Biondi-Zoccai, G., Van Tassell, B. W., & Abbate, A. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.108053 · Cited by 328
Intracranial atherosclerotic stenosis: risk factors, diagnosis, and treatment
Gutierrez, J., Turan, T. N., Hoh, B. L., & Chimowitz, M. I. (2022) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00376-8 · Cited by 321
Bouabdallaoui, N., Tardif, J.-C., Waters, D. D., Pinto, F. J., Maggioni, A. P., Diaz, R., Berry, C., Koenig, W., Lopez-Sendon, J., Gamra, H., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa659 · Cited by 318
“The secondary endpoints consisted of the components of the primary efficacy endpoint, all-cause death, and a composite of CV death, resuscitated cardiac arrest, MI, or stroke.(9) Exploratory endpoints included all coronary revascularizations, including both elective and urgent coronary revascularizations.”
BackgroundMethodInfluentialSelf-citationKologrivova, I., Shtatolkina, M., Suslova, T., & Ryabov, V. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.664457 · Cited by 317
Inflammation in Atherosclerosis—No Longer a Theory
Libby, P. (2021) · Clinical Chemistry · doi:10.1093/clinchem/hvaa275 · Cited by 314
2023 ESC Guidelines for the management of acute coronary syndromes
Byrne, R. A., Rossello, X., Coughlan, J. J., Barbato, E., Berry, C., Chieffo, A., Claeys, M. J., Dan, G.-A., Dweck, M. R., Galbraith, M., et al. (2024) · European Heart Journal: Acute Cardiovascular Care · doi:10.1093/ehjacc/zuad107 · Cited by 314
Self-citationUric Acid in Inflammation and the Pathogenesis of Atherosclerosis
Kimura, Y., Tsukui, D., & Kono, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212394 · Cited by 309
“In randomized control trials (RCTs), ULT significantly suppressed out flares in patients with asymptomatic hyperuricemia.”
BackgroundInfluentialMacrophages in cardiac remodelling after myocardial infarction
Yap, J., Irei, J., Lozano-Gerona, J., Vanapruks, S., Bishop, T., & Boisvert, W. A. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00823-5 · Cited by 307
Wong, N. D., Budoff, M. J., Ferdinand, K., Graham, I. M., Michos, E. D., Reddy, T., Shapiro, M. D., & Toth, P. P. (2022) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2022.100335 · Cited by 302
“treatment with either low-dose colchicine or placebo (109).”
Abbate, A., Trankle, C. R., Buckley, L. F., Lipinski, M. J., Appleton, D., Kadariya, D., Canada, J. M., Carbone, S., Roberts, C. S., Abouzaki, N., et al. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.014941 · Cited by 300
Inflammation, Cholesterol, Lipoprotein(a), and 30-Year Cardiovascular Outcomes in Women
Ridker, P. M., Moorthy, M. V., Cook, N. R., Rifai, N., Lee, I.-M., & Buring, J. E. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2405182 · Cited by 296
Hallmarks of cardiovascular ageing
Abdellatif, M., Rainer, P. P., Sedej, S., & Kroemer, G. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00881-3 · Cited by 274
“In patients with cardiovascular disease, targeting inflammation by either inhibiting the NLPR3 inflammasome with colchicine 374 or neutralizing its major cytokine product IL-1β with the anti-IL-1β antibody canakinumab 375,376 , has been shown to be effective for secondary prevention of…”
BackgroundSystemic inflammation after stroke: implications for post‐stroke comorbidities
Simats, A., & Liesz, A. (2022) · EMBO Molecular Medicine · doi:10.15252/emmm.202216269 · Cited by 276
Colchicine in Cardiovascular Disease: In-Depth Review
Deftereos, S. G., Beerkens, F. J., Shah, B., Giannopoulos, G., Vrachatis, D. A., Giotaki, S. G., Siasos, G., Nicolas, J., Arnott, C., Patel, S., et al. (2022) · Circulation · doi:10.1161/circulationaha.121.056171 · Cited by 273
Self-citationFiolet, A. T. L., Opstal, T. S. J., Mosterd, A., Eikelboom, J. W., Jolly, S. S., Keech, A. C., Kelly, P., Tong, D. C., Layland, J., Nidorf, S. M., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab115 · Cited by 253
“Safety information is summarized in Figure 4 and was available from three trials: COLCOT, COPS, and LoDoCo2.(13,14,25) Overall, colchicine was not associated with an increased risk for hospitalization for infection in general (RR 1.”
BackgroundMethodInfluentialWatts, G. F., Gidding, S. S., Hegele, R. A., Raal, F. J., Sturm, A. C., Jones, L. K., Sarkies, M. N., Al-Rasadi, K., Blom, D. J., Daccord, M., et al. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00892-0 · Cited by 250
“In patients with FH and established clinical ASCVD, the use of aspirin, colchicine and eicosapentaenoic acid should be implemented according to evidence-based guidelines for secondary prevention of ASCVD 172–178 .”
MethodLopes, M. I., Bonjorno, L. P., Giannini, M. C., Amaral, N. B., Menezes, P. I., Dib, S. M., Gigante, S. L., Benatti, M. N., Rezek, U. C., Emrich-Filho, L. L., et al. (2021) · RMD Open · doi:10.1136/rmdopen-2020-001455 · Cited by 252
Rajendran, A., Minhas, A. S., Kazzi, B., Varma, B., Choi, E., Thakkar, A., & Michos, E. D. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.117269 · Cited by 243
Inflammation and resolution signaling in cardiac repair and heart failure
Halade, G. V., & Lee, D. H. (2022) · eBioMedicine · doi:10.1016/j.ebiom.2022.103992 · Cited by 241
Coronary heart disease risk: Low-density lipoprotein and beyond
Shaya, G. E., Leucker, T. M., Jones, S. R., Martin, S. S., & Toth, P. P. (2022) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2021.04.002 · Cited by 236
Mechanisms of Stroke in COVID-19
Spence, J. D., de Freitas, G. R., Pettigrew, L. C., Ay, H., Liebeskind, D. S., Kase, C. S., Del Brutto, O. H., Hankey, G. J., & Venketasubramanian, N. (2020) · Cerebrovascular Diseases · doi:10.1159/000509581 · Cited by 240
Myocardial ischemia/reperfusion: Translational pathophysiology of ischemic heart disease
Heusch, G. (2024) · Med · doi:10.1016/j.medj.2023.12.007 · Cited by 228
Targeting innate immunity-driven inflammation in CKD and cardiovascular disease
Speer, T., Dimmeler, S., Schunk, S. J., Fliser, D., & Ridker, P. M. (2022) · Nature Reviews Nephrology · doi:10.1038/s41581-022-00621-9 · Cited by 232
Perivascular adipose tissue as a source of therapeutic targets and clinical biomarkers
Antoniades, C., Tousoulis, D., Vavlukis, M., Fleming, I., Duncker, D. J., Eringa, E., Manfrini, O., Antonopoulos, A. S., Oikonomou, E., Padró, T., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad484 · Cited by 224
Düsing, P., Zietzer, A., Goody, P. R., Hosen, M. R., Kurts, C., Nickenig, G., & Jansen, F. (2021) · Journal of Molecular Medicine · doi:10.1007/s00109-021-02037-7 · Cited by 224
Hegemony of inflammation in atherosclerosis and coronary artery disease
Attiq, A., Afzal, S., Ahmad, W., & Kandeel, M. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176338 · Cited by 220
Everett, B. M., MacFadyen, J. G., Thuren, T., Libby, P., Glynn, R. J., & Ridker, P. M. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.08.011 · Cited by 220
Inflammation and Stroke Risk: A New Target for Prevention
Kelly, P. J., Lemmens, R., & Tsivgoulis, G. (2021) · Stroke · doi:10.1161/strokeaha.121.034388 · Cited by 216
Karunakaran, D., Nguyen, M.-A., Geoffrion, M., Vreeken, D., Lister, Z., Cheng, H. S., Otte, N., Essebier, P., Wyatt, H., Kandiah, J. W., et al. (2021) · Circulation · doi:10.1161/circulationaha.118.038379 · Cited by 216
Chalmers, J. D., Crichton, M. L., Goeminne, P. C., Cao, B., Humbert, M., Shteinberg, M., Antoniou, K. M., Ulrik, C. S., Parks, H., Wang, C., et al. (2021) · European Respiratory Journal · doi:10.1183/13993003.00048-2021 · Cited by 219
Colchicine in Patients with Chronic Coronary Disease
(2021) · New England Journal of Medicine · doi:10.1056/nejmc2034992 · Cited by 217
Cardiovascular disease in diabetes, beyond glucose
Eckel, R. H., Bornfeldt, K. E., & Goldberg, I. J. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.07.001 · Cited by 212
(2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00435-5 · Cited by 211
The Lancet Commission on rethinking coronary artery disease: moving from ischaemia to atheroma
Zaman, S., Wasfy, J. H., Kapil, V., Ziaeian, B., Parsonage, W. A., Sriswasdi, S., Chico, T. J. A., Capodanno, D., Colleran, R., Sutton, N. R., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)00055-8 · Cited by 203
Wang, Y., Liu, X., Shi, H., Yu, Y., Yu, Y., Li, M., & Chen, R. (2020) · Clinical and Translational Medicine · doi:10.1002/ctm2.13 · Cited by 202
“5 mg colchicine daily, compared to that in the placebo-treated patients.(2) Cholecalciferol cholesterol emulsion, a commercialized drug used to treat vitamin D deficiency in children, alleviated autoimmune myocarditis via pyroptosis inhibition in mice.”
BackgroundSaito, Y., Oyama, K., Tsujita, K., Yasuda, S., & Kobayashi, Y. (2023) · Journal of Cardiology · doi:10.1016/j.jjcc.2022.07.003 · Cited by 197
Imazio, M., & Nidorf, M. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab221 · Cited by 196
“03).(21,44) Two additional studies of colchicine in ACS were published in 2020: the COLCHICINE-PCI trial(46) and the COPS trial.”
BackgroundLeft Ventricular Thrombus Following Acute Myocardial Infarction
Camaj, A., Fuster, V., Giustino, G., Bienstock, S. W., Sternheim, D., Mehran, R., Dangas, G. D., Kini, A., Sharma, S. K., Halperin, J., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.01.011 · Cited by 191
Sex- and Gender-Based Pharmacological Response to Drugs
Mauvais-Jarvis, F., Berthold, H. K., Campesi, I., Carrero, J.-J., Dhakal, S., Franconi, F., Gouni-Berthold, I., Heiman, M. L., Kautzky-Willer, A., Klein, S. L., et al. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000206 · Cited by 192
“A recent RCT reporting positive effects of colchicine for MI included only 20% women and did not segregate the results by sex (Tardif et al., 2019).”
BackgroundLow-Dose Colchicine for Secondary Prevention of Coronary Artery Disease
Nelson, K., Fuster, V., & Ridker, P. M. (2023) · JACC · doi:10.1016/j.jacc.2023.05.055 · Cited by 191
Metadata
- Authors
- Tardif, J.-C., Kouz, S., Waters, D. D., Bertrand, O. F., Diaz, R., Maggioni, A. P., Pinto, F. J., Ibrahim, R., Gamra, H., Kiwan, G. S., Berry, C., López-Sendón, J., Ostadal, P., Koenig, W., Angoulvant, D., Grégoire, J. C., Lavoie, M.-A., Dubé, M.-P., Rhainds, D., Provencher, M., Blondeau, L., Orfanos, A., L’Allier, P. L., Guertin, M.-C., & Roubille, F.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- From the Montreal Heart Institute (J.-C.T., R.I., J.C.G., M.-A.L., M.-P.D., D.R., P.L.L.) and the Montreal Health Innovations Coordinating Center (M.P., L.B., A.O., M.-C.G.), Montreal, Centre Hospitalier Régional de Lanaudière, Joliette (S.K.), and Institut de Cardiologie et Pneumologie de Québec, Quebec City (O.F.B.) — all in Canada; San Francisco General Hospital, San Francisco (D.D.W.); Estudios Clínicos Latinoamérica, Rosario, Argentina (R.D.); Associazione Nazionale Medici Cardiologi...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-12-26
- Volume
- 381
- Issue
- 26
- Pages
- 2497-2505
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2986700515
- Cited by
- 3,159
- References
- 20
- Citations by year
- 2026: 505 · 2025: 519 · 2024: 445 · 2023: 415 · 2022: 414 · 2021: 485 · 2020: 361 · 2019: 10
- FWCI
- 230.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- HAL (submittedVersion, other-oa)
- eScholarship (California Digital Library) (submittedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion)
- Funders
- Government of Quebec
- Canadian Institutes of Health Research
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Keywords
- colchicine, myocardial infarction, anti-inflammatory therapy, inflammation in atherosclerosis, cardiovascular mortality, major adverse cardiovascular events, stroke, angina pectoris, diarrhea, pneumonia, drug safety, low-dose colchicine, secondary prevention, coronary revascularization, cardiac arrest, myocardial infarction recurrence, cardiovascular risk reduction, cost-effectiveness, quality of life
- MeSH terms
- Aged, Angina Pectoris, Anti-Inflammatory Agents, C-Reactive Protein, Cardiovascular Diseases, Colchicine, Double-Blind Method, Female, Humans, Male, Middle Aged, Myocardial Infarction, Recurrence, Biomarkers, Incidence, Proportional Hazards Models, Stroke, Kaplan-Meier Estimate, Intention to Treat Analysis, Percutaneous Coronary Intervention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

